Trabectedin, Doxorubicin and Olaratumab in Patients With Metastatic or Recurrent Leiomyosarcoma
Status:
Withdrawn
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
This study seeks to determine if addition of trabectedin (T) to combination doxorubicin (D)
and olaratumab (O), is feasible and tolerable with antitumor activity in metastatic or
recurrent Leiomyosarcomas (LMS) patients who have limited therapeutic options.